메뉴 건너뛰기




Volumn 17, Issue 2, 2013, Pages 108-112

Profiling serum HER-2/NEU in prostate cancer

Author keywords

Advanced disease; ECD; HER2 neu oncoprotein; Metastatic; Prostate cancer; Serum

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

EID: 84881265388     PISSN: 11084189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (12)

References (52)
  • 2
    • 0033958595 scopus 로고    scopus 로고
    • The prostate: Diagnostic evaluation of metastatic disease
    • Yu KK, Hawkins RA. The prostate: diagnostic evaluation of metastatic disease. Radiol Clin North Am. 2000; 38: 139-157, ix.
    • (2000) Radiol Clin North Am , vol.38
    • Yu, K.K.1    Hawkins, R.A.2
  • 3
    • 33947258834 scopus 로고    scopus 로고
    • Natural history of biochemical recurrence after radical prostatectomy: Risk assessment for secondary therapy
    • Simmons MN, Stephenson AJ, Klein EA. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Eur Urol. 2007; 51: 1175-1184.
    • (2007) Eur Urol , vol.51 , pp. 1175-1184
    • Simmons, M.N.1    Stephenson, A.J.2    Klein, E.A.3
  • 4
    • 34547655304 scopus 로고    scopus 로고
    • Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy
    • Sandler HM, Eisenberger MA. Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy. J Urol. 2007; 178: S20-S24.
    • (2007) J Urol , vol.178
    • Sandler, H.M.1    Eisenberger, M.A.2
  • 5
    • 39749137117 scopus 로고    scopus 로고
    • Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer
    • Ross RW, Oh WK, Xie W, Pomerantz M, Nakabayashi M, Sartor O, et al. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2008; 26: 842-847.
    • (2008) J Clin Oncol , vol.26 , pp. 842-847
    • Ross, R.W.1    Oh, W.K.2    Xie, W.3    Pomerantz, M.4    Nakabayashi, M.5    Sartor, O.6
  • 6
    • 4744347762 scopus 로고    scopus 로고
    • Mechanisms of androgen-refractory prostate cancer
    • Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N Engl J Med. 2004; 351: 1488-1490.
    • (2004) N Engl J Med , vol.351 , pp. 1488-1490
    • Debes, J.D.1    Tindall, D.J.2
  • 8
    • 0035496220 scopus 로고    scopus 로고
    • The development of androgen independent prostate cancer
    • Feldman BJ, Feldman D. The development of androgen independent prostate cancer. Nat Rev Cancer. 2001; 1: 34-45.
    • (2001) Nat Rev Cancer , vol.1 , pp. 34-45
    • Feldman, B.J.1    Feldman, D.2
  • 9
    • 0034671668 scopus 로고    scopus 로고
    • HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway
    • Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH, et al. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res. 2000; 60: 6841-6845.
    • (2000) Cancer Res , vol.60 , pp. 6841-6845
    • Wen, Y.1    Hu, M.C.2    Makino, K.3    Spohn, B.4    Bartholomeusz, G.5    Yan, D.H.6
  • 10
    • 7944234374 scopus 로고    scopus 로고
    • HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability
    • Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat, J, Sawyers CL. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell. 2004; 6: 517-527.
    • (2004) Cancer Cell , vol.6 , pp. 517-527
    • Mellinghoff, I.K.1    Vivanco, I.2    Kwon, A.3    Tran, C.4    Wongvipat, J.5    Sawyers, C.L.6
  • 11
    • 77953120700 scopus 로고    scopus 로고
    • Prostate specific antigen at the initial diagnosis of metastasis to bone in patients after radical prostatectomy
    • Loeb S, Makarov DV, Schaeffer EM, Humphreys EB, Walsh PC. Prostate specific antigen at the initial diagnosis of metastasis to bone in patients after radical prostatectomy. J Urol. 2010; 184: 157-161.
    • (2010) J Urol , vol.184 , pp. 157-161
    • Loeb, S.1    Makarov, D.V.2    Schaeffer, E.M.3    Humphreys, E.B.4    Walsh, P.C.5
  • 12
    • 34547903643 scopus 로고    scopus 로고
    • Blood biomarkers for prostate cancer detection and prognosis
    • Shariat SF, Karam JA, Roehrbom CG. Blood biomarkers for prostate cancer detection and prognosis. Future Oncol. 2007; 3: 449-461.
    • (2007) Future Oncol , vol.3 , pp. 449-461
    • Shariat, S.F.1    Karam, J.A.2    Roehrbom, C.G.3
  • 13
    • 68549090701 scopus 로고    scopus 로고
    • New molecular biomarkers for the prognosis and management of prostate cancer--the post PSA era
    • Bickers B, Aukim-Hastie C. New molecular biomarkers for the prognosis and management of prostate cancer--the post PSA era. Anticancer Res. 2009; 29: 3289-3298.
    • (2009) Anticancer Res , vol.29 , pp. 3289-3298
    • Bickers, B.1    Aukim-Hastie, C.2
  • 14
    • 0034600849 scopus 로고    scopus 로고
    • The ErbB signaling network: Receptor heterodimerization in development and cancer
    • Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000; 19: 3159-3167.
    • (2000) EMBO J , vol.19 , pp. 3159-3167
    • Olayioye, M.A.1    Neve, R.M.2    Lane, H.A.3    Hynes, N.E.4
  • 15
  • 16
  • 17
    • 0025281906 scopus 로고
    • Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer
    • Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 1990; 50: 4087-4091.
    • (1990) Cancer Res , vol.50 , pp. 4087-4091
    • Berchuck, A.1    Kamel, A.2    Whitaker, R.3    Kerns, B.4    Olt, G.5    Kinney, R.6
  • 19
    • 0033118889 scopus 로고    scopus 로고
    • Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of 20 human breast cancers
    • Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of 20 human breast cancers. Oncogene. 1999; 18: 2241-2251.
    • (1999) Oncogene , vol.18 , pp. 2241-2251
    • Pegram, M.1    Hsu, S.2    Lewis, G.3    Pietras, R.4    Beryt, M.5    Sliwkowski, M.6
  • 20
    • 0032825577 scopus 로고    scopus 로고
    • Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: Evidence for receptor-enhanced chemosensitivity
    • Pegram MD, Slamon DJ. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. Semin Oncol. 1999; 26: 89-95.
    • (1999) Semin Oncol , vol.26 , pp. 89-95
    • Pegram, M.D.1    Slamon, D.J.2
  • 22
    • 0000153682 scopus 로고    scopus 로고
    • The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials
    • Mass R, Sanders C, Kasian C, Johnson L, Everett T, Anderson S. The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials. Proc Am Soc Clin Oncol. 2000; 19: 75a.
    • (2000) Proc Am Soc Clin Oncol , vol.19
    • Mass, R.1    Sanders, C.2    Kasian, C.3    Johnson, L.4    Everett, T.5    Anderson, S.6
  • 23
    • 0028955388 scopus 로고
    • Epidermal growth factor-related peptides and their receptors in human malignancies
    • Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995; 19: 183-232.
    • (1995) Crit Rev Oncol Hematol , vol.19 , pp. 183-232
    • Salomon, D.S.1    Brandt, R.2    Ciardiello, F.3    Normanno, N.4
  • 24
    • 0036847724 scopus 로고    scopus 로고
    • Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer
    • Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res. 2002; 8: 3438-3444.
    • (2002) Clin Cancer Res , vol.8 , pp. 3438-3444
    • Di Lorenzo, G.1    Tortora, G.2    D'Armiento, F.P.3    De Rosa, G.4    Staibano, S.5    Autorino, R.6
  • 26
    • 0034808673 scopus 로고    scopus 로고
    • HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer
    • Osman I, Scher HI, Drobnjak M, Verbel D, Morris M, Agus D, et al. HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin Cancer Res. 2001; 7: 2643-2647.
    • (2001) Clin Cancer Res , vol.7 , pp. 2643-2647
    • Osman, I.1    Scher, H.I.2    Drobnjak, M.3    Verbel, D.4    Morris, M.5    Agus, D.6
  • 28
    • 0033022342 scopus 로고    scopus 로고
    • A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signalling by the HER-2/neu tyrosine kinase
    • Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signalling by the HER-2/neu tyrosine kinase. Nat Med. 1999; 5: 280-285.
    • (1999) Nat Med , vol.5 , pp. 280-285
    • Craft, N.1    Shostak, Y.2    Carey, M.3    Sawyers, C.L.4
  • 29
    • 0034614108 scopus 로고    scopus 로고
    • Her-2-neu expression and progression toward androgen independence in human prostate cancer
    • Signoretti S, Montironi R, Manola J, Altimari A, Tam C, Bubley G, et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst. 2000; 92: 1918-1925.
    • (2000) J Natl Cancer Inst , vol.92 , pp. 1918-1925
    • Signoretti, S.1    Montironi, R.2    Manola, J.3    Altimari, A.4    Tam, C.5    Bubley, G.6
  • 30
    • 33745862393 scopus 로고    scopus 로고
    • Prognostic significance of immunohistochemical expression of the Her-2/neu oncoprotein in bone metastatic prostate cancer
    • Nishio Y, Yamada Y, Kokubo H, Nakamura K, Aoki S, Taki T, et al. Prognostic significance of immunohistochemical expression of the Her-2/neu oncoprotein in bone metastatic prostate cancer. Urology. 2006; 68: 110-115.
    • (2006) Urology , vol.68 , pp. 110-115
    • Nishio, Y.1    Yamada, Y.2    Kokubo, H.3    Nakamura, K.4    Aoki, S.5    Taki, T.6
  • 31
    • 0032794761 scopus 로고    scopus 로고
    • Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastatic prostate cancer
    • Morote J, de Torres I, Caceres C, Vallejo C, Schwartz S Jr, Reventos J. Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastatic prostate cancer. Int J Cancer. 1999; 84: 421-425.
    • (1999) Int J Cancer , vol.84 , pp. 421-425
    • Morote, J.1    de Torres, I.2    Caceres, C.3    Vallejo, C.4    Schwartz Jr., S.5    Reventos, J.6
  • 33
    • 0034833701 scopus 로고    scopus 로고
    • Her-2/neu expression in prostate cancer: High level of expression associated with exposure to hormone therapy and androgen independent disease
    • Shi Y, Brands FH, Chatterjee S, Feng AC, Groshen S, Schewe J, et al. Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. J Urol. 2001; 166: 1514-1519.
    • (2001) J Urol , vol.166 , pp. 1514-1519
    • Shi, Y.1    Brands, F.H.2    Chatterjee, S.3    Feng, A.C.4    Groshen, S.5    Schewe, J.6
  • 34
    • 3242755999 scopus 로고    scopus 로고
    • Molecular alterations associated with LNCaP cell progression to androgen independence
    • Shi XB, Ma AH, Tepper CG, Xia L, Gregg JP, Gandour-Edwards R, et al. Molecular alterations associated with LNCaP cell progression to androgen independence. Prostate. 2004; 60: 257-271.
    • (2004) Prostate , vol.60 , pp. 257-271
    • Shi, X.B.1    Ma, A.H.2    Tepper, C.G.3    Xia, L.4    Gregg, J.P.5    Gandour-Edwards, R.6
  • 35
    • 1342280433 scopus 로고    scopus 로고
    • Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence
    • Hernes E, Fosså SD, Berner A, Otnes B, Nesland JM. Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence. Br J Cancer. 2004; 90: 449-454.
    • (2004) Br J Cancer , vol.90 , pp. 449-454
    • Hernes, E.1    Fosså, S.D.2    Berner, A.3    Otnes, B.4    Nesland, J.M.5
  • 37
    • 2342456382 scopus 로고    scopus 로고
    • Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: Final results from the California Cancer Consortium Screening and Phase II Trial
    • Lara PN Jr, Chee KG, Longmate J, Ruel C, Meyers FJ, Gray CR, et al. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer. 2004; 100: 2125-2131.
    • (2004) Cancer , vol.100 , pp. 2125-2131
    • Lara Jr., P.N.1    Chee, K.G.2    Longmate, J.3    Ruel, C.4    Meyers, F.J.5    Gray, C.R.6
  • 38
    • 3943104783 scopus 로고    scopus 로고
    • The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial
    • Ziada A, Barqawi A, Glode LM, Varella-Garcia M, Crighton F, Majeski S, et al. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate. 2004; 60: 332-337.
    • (2004) Prostate , vol.60 , pp. 332-337
    • Ziada, A.1    Barqawi, A.2    Glode, L.M.3    Varella-Garcia, M.4    Crighton, F.5    Majeski, S.6
  • 39
    • 33846927744 scopus 로고    scopus 로고
    • Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapynaive patients with hormone-refractory prostate cancer
    • de Bono JS, Bellmunt J, Attard G, Droz JP, Miller K, Flechon A, et al. Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapynaive patients with hormone-refractory prostate cancer. J Clin Oncol. 2007; 25: 257-262.
    • (2007) J Clin Oncol , vol.25 , pp. 257-262
    • de Bono, J.S.1    Bellmunt, J.2    Attard, G.3    Droz, J.P.4    Miller, K.5    Flechon, A.6
  • 41
    • 38849155715 scopus 로고    scopus 로고
    • Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel
    • Domingo-Domenech J, Fernandez PL, Filella X, Martinez-Fernandez A, Molina R, Fernandez E, et al. Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel. Ann Oncol. 2008; 19: 269-275.
    • (2008) Ann Oncol , vol.19 , pp. 269-275
    • Domingo-Domenech, J.1    Fernandez, P.L.2    Filella, X.3    Martinez-Fernandez, A.4    Molina, R.5    Fernandez, E.6
  • 42
    • 0028170155 scopus 로고
    • Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma
    • Myers RB, Srivastava S, Oelschlager DK, Grizzle WE. Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J Natl Cancer Inst. 1994; 86: 1140-1145.
    • (1994) J Natl Cancer Inst , vol.86 , pp. 1140-1145
    • Myers, R.B.1    Srivastava, S.2    Oelschlager, D.K.3    Grizzle, W.E.4
  • 43
    • 0036625856 scopus 로고    scopus 로고
    • Serum HER-2/neu extracellular domain levels in men presenting with suspected prostate cancer
    • Croal BL, Mitchell IDC, Mutch WJ, Dickie A, Cohen N, Ross IS. Serum HER-2/neu extracellular domain levels in men presenting with suspected prostate cancer. UroOncology 2002; 2:99-102.
    • (2002) UroOncology , vol.2 , pp. 99-102
    • Croal, B.L.1    Mitchell, I.D.C.2    Mutch, W.J.3    Dickie, A.4    Cohen, N.5    Ross, I.S.6
  • 44
    • 34848863777 scopus 로고    scopus 로고
    • Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer
    • Shariat SF, Bensalah K, Karam JA, Roehrborn CG, Gallina A, Lotan Y, et al. Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer. Clin Cancer Res. 2007; 13: 5377-5384.
    • (2007) Clin Cancer Res , vol.13 , pp. 5377-5384
    • Shariat, S.F.1    Bensalah, K.2    Karam, J.A.3    Roehrborn, C.G.4    Gallina, A.5    Lotan, Y.6
  • 45
    • 33748769249 scopus 로고    scopus 로고
    • Pretreatment serum level of HER2/neu as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy
    • Okegawa T, Kinjo M, Nutahara K, HIigashihara E. Pretreatment serum level of HER2/neu as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy. Int J Urol. 2006; 13: 1197-1201.
    • (2006) Int J Urol , vol.13 , pp. 1197-1201
    • Okegawa, T.1    Kinjo, M.2    Nutahara, K.3    Hiigashihara, E.4
  • 46
    • 0030888544 scopus 로고    scopus 로고
    • C-erbB-2 oncoprotein: A potential biomarker of advanced prostate cancer
    • Arai Y, Yoshiki T, Yoshida O. C-erbB-2 oncoprotein: a potential biomarker of advanced prostate cancer. Prostate. 1997; 30: 195-201.
    • (1997) Prostate , vol.30 , pp. 195-201
    • Arai, Y.1    Yoshiki, T.2    Yoshida, O.3
  • 47
    • 0023834161 scopus 로고
    • Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan
    • Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 1988; 61: 195-202.
    • (1988) Cancer , vol.61 , pp. 195-202
    • Soloway, M.S.1    Hardeman, S.W.2    Hickey, D.3    Raymond, J.4    Todd, B.5    Soloway, S.6
  • 48
    • 0037316605 scopus 로고    scopus 로고
    • Matrix metalloproteinases, angiogenesis, and cancer: Commentary re: A. C. Lockhart et al., Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor
    • Clin. Cancer Res., 9: 00-00, 2003
    • Rundhaug JE. Matrix metalloproteinases, angiogenesis, and cancer: commentary re: A. C. Lockhart et al., Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin. Cancer Res., 9: 00-00, 2003. Clin Cancer Res. 2003; 9: 551-554.
    • (2003) Clin Cancer Res , vol.9 , pp. 551-554
    • Rundhaug, J.E.1
  • 49
    • 64549128211 scopus 로고    scopus 로고
    • Comparison of serum HER2/neu with immunohistochemical HER2/neu expression for the prediction of biochemical progression in metastatic prostate cancer
    • Tambo M, Higashihara E, Terado Y, Nutahara K, Okegawa T. Comparison of serum HER2/neu with immunohistochemical HER2/neu expression for the prediction of biochemical progression in metastatic prostate cancer. Int J Urol. 2009; 16: 369-374.
    • (2009) Int J Urol , vol.16 , pp. 369-374
    • Tambo, M.1    Higashihara, E.2    Terado, Y.3    Nutahara, K.4    Okegawa, T.5
  • 50
    • 0036294369 scopus 로고    scopus 로고
    • C-erbB2 oncoprotein and its soluble ectodomain: A new potential tumor marker for prognosis early detection and monitoring patients undergoing Herceptin treatment
    • Wu JT. C-erbB2 oncoprotein and its soluble ectodomain: a new potential tumor marker for prognosis early detection and monitoring patients undergoing Herceptin treatment. Clin Chim Acta. 2002; 322: 11-19.
    • (2002) Clin Chim Acta , vol.322 , pp. 11-19
    • Wu, J.T.1
  • 51
    • 27744600091 scopus 로고    scopus 로고
    • Serum levels of shed Her2/neu protein in men with prostate cancer correlate with disease progression
    • Osman I, Mikhail M, Shuch B, Clute M, Cheli CD, Ghani F, et al. Serum levels of shed Her2/neu protein in men with prostate cancer correlate with disease progression. J Urol. 2005; 174: 2174-2177.
    • (2005) J Urol , vol.174 , pp. 2174-2177
    • Osman, I.1    Mikhail, M.2    Shuch, B.3    Clute, M.4    Cheli, C.D.5    Ghani, F.6
  • 52
    • 4243578322 scopus 로고    scopus 로고
    • Elevated serum HER-2/neu in metastatic prostate cancer
    • Shin BY, Leitzel K, Ali SM et al. Elevated serum HER-2/neu in metastatic prostate cancer. Proc Am Soc Clin Oncol. 2002; 21: 429.
    • (2002) Proc Am Soc Clin Oncol , vol.21 , pp. 429
    • Shin, B.Y.1    Leitzel, K.2    Ali, S.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.